Mycobacterial Cell Wall Stimulant in the Treatment of Squamous Cell Carcinoma: A Case Series Regarding Treatment in Equine, Bovine and Caprine Patients.
Authors: Halleran Jennifer, Yau Katie, Paegelow Jillian, Streeter Robert, Foster Derek
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: Mycobacterial Cell Wall Stimulant for Equine, Bovine and Caprine Squamous Cell Carcinoma Squamous cell carcinoma remains a significant dermatological challenge in large animals, particularly when conventional treatments such as surgery or cryotherapy prove impractical or unfeasible, prompting investigation into immunomodulatory alternatives. This retrospective case series examined seven patients (three equine, two bovine and two caprine) treated with intravenous and intralesional mycobacterial cell wall (MCW) stimulant injections, either alone or combined with other therapies, with medical records reviewed across two veterinary teaching hospitals. Whilst some lesion size reduction was observed during treatment (median duration 56.5 days), long-term resolution proved unlikely, with three of seven patients euthanised and significant complications arising in 43% of cases. The high incidence of adverse effects and poor prognosis for sustained remission suggest MCW should not be considered a reliable primary or adjunctive therapy for SCC in these species at present. Given the heterogeneous patient population and limited sample size, further controlled research is needed before recommending this immunomodulatory approach, and practitioners should continue prioritising conventional treatments where feasible or considering palliative management strategies for unsuitable candidates.
Read the full abstract on PubMed
Practical Takeaways
- •MCW immunotherapy may temporarily reduce SCC lesion size in some cases, but should not be considered a reliable long-term solution for SCC management
- •Risk of serious complications is substantial (43% in this series), so informed client consent and careful monitoring are essential if this therapy is attempted
- •Current evidence does not support MCW as a standard alternative to surgery or cryotherapy for SCC; traditional treatments remain preferable where feasible
Key Findings
- •Mycobacterial cell wall stimulant treatment resulted in lesion size reduction in some cases but long-term resolution was unlikely
- •3 of 7 patients were euthanized during or after treatment course
- •Significant complications occurred in 3 of 7 patients (43%)
- •Median treatment duration was 56.5 days across equine, bovine, and caprine patients